Contrast-enhanced electron-beam CT yields promising results concerning the visualization of coronary artery stenoses.

The aim of this study was to evaluate the association between carotid and coronary atherosclerosis and their diagnostic value for predicting angiographically significant coronary artery disease (CAD). We investigated 80 subjects (mean age 55 +/- 8 years) by electron beam computed tomography (EBT), the most sensitive technology for noninvasive detection of coronary calcification (a marker of coronary atherosclerosis); by carotid sonography; and by coronary angiography. Carotid ultrasound was performed with a 7.5 MHz Duplex probe, EBT was done with an EVOLUTION(R) scanner. In 47 subjects, coronary calcification as well as carotid atherosclerosis was present. Thirteen subjects showed isolated coronary calcification, 10 had isolated carotid atherosclerosis, and 10 showed neither coronary calcification nor carotid atheroscleroosis. The association between carotid atherosclerosis and CAD as well as the relationship between coronary calcification and CAD were statistically significant (p < 0.05), but the correlation between coronary calcification and CAD was higher than between carotid atherosclerosis and CAD (Pearson contingency coefficient: 0.34 vs 0.86). In subjects without carotid atherosclerosis, the mean area of coronary calcificiation was significantly (p < 0.01) lower (41 mm2) than in subjects with carotid atherosclerosis (113 mm2). For noninvasive detection of CAD, electron beam CT was superior to carotid sonography on sensitivity (95% vs 78%) and specificity (81% vs 48%). Former studies suggested that sonography of extracoronary vessels could aid in screening for CAD. In our study, the sonographic status of carotid arteries was associated with cardiovascular atherosclerosis but it did not allow us to make a judgment about the presence of CAD with sufficient reliability and it was inferior to electron beam CT as a noninvasive marker of CAD.

Tuberculosis (TB) is one of the leading causes of death by an infectious disease. It remains a major health burden worldwide, in part due to misdiagnosis. Therefore, improved diagnostic tests allowing the faster and more reliable diagnosis of patients with active TB are urgently needed. This prospective study examined the performance of the new molecular whole-blood test T-Track® TB, which relies on the combined evaluation of IFNG and CXCL10 mRNA levels, and compared it to that of the QuantiFERON®-TB Gold Plus (QFT-Plus) enzyme-linked immunosorbent assay (ELISA). Diagnostic accuracy and agreement analyses were conducted on the whole blood of 181 active TB patients and 163 non-TB controls. T-Track® TB presented sensitivity of 94.9% and specificity of 93.8% for the detection of active TB vs. non-TB controls. In comparison, the QFT-Plus ELISA showed sensitivity of 84.3%. The sensitivity of T-Track® TB was significantly higher (p < 0.001) than that of QFT-Plus. The overall agreement of T-Track® TB with QFT-Plus to diagnose active TB was 87.9%. Out of 21 samples with discordant results, 19 were correctly classified by T-Track® TB while misclassified by QFT-Plus (T-Track® TB-positive/QFT-Plus-negative), and two samples were misclassified by T-Track® TB while correctly classified by QFT-Plus (T-Track® TB-negative/QFT-Plus-positive). Our results demonstrate the excellent performance of the T-Track® TB molecular assay and its suitability to accurately detect TB infection and discriminate active TB patients from non-infected controls.

No abstract

No abstract